Physician profile
Brian James Munley
NPI 1093775793
$7,114.45
in general payments reported to CMS, 2019-2025
34 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $226 · 2021: $663 · 2022: $1,380 · 2023: $1,208 · 2024: $1,142 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $750.74 | 2019-2025 | |
| Amgen INC. | $659.51 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $490.56 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $488.86 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $484.52 | 2019-2023 | |
| Pfizer INC. | $471.02 | 2019-2025 | |
| Esperion Therapeutics, INC. | $438.23 | 2021-2025 | Nexletol |
| Irhythm Technologies, INC. | $402.56 | 2019-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $369.35 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.51 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $349.51 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $227.55 | 2019-2022 | |
| Novo Nordisk INC | $219.38 | 2021-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $187.64 | 2022-2025 | |
| Boston Scientific Corporation | $183.87 | 2019-2024 | Watchman Flx, Watchman Access System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $157.16 | 2019-2024 | Barostim Neo System |
| Amarin Pharma, INC. | $121.43 | 2019-2022 | |
| Abbott Laboratories | $98.83 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Scpharmaceuticals INC. | $95.46 | 2024 | |
| Lundbeck LLC | $93.07 | 2019-2020 | |
| Heartflow, INC. | $75.83 | 2023-2024 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $51.94 | 2019 | |
| Medtronic, INC. | $51.15 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $46.02 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $40.51 | 2024 | |
| Vifor Pharma, INC. | $34.92 | 2022 | |
| Kestra Medical Technology Services, INC. | $25.02 | 2024 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $23.63 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Shield Therapeutics INC | $21.19 | 2023 | Accrufer |
| Gilead Sciences, INC. | $17.88 | 2019 | |
| Philips North America LLC | $16.58 | 2022 | |
| Edwards Lifesciences Corporation | $15.67 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bardy Diagnostics, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Munley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.